Literature DB >> 9874180

Intrathecal therapy of leptomeningeal CEM T-cell lymphoma in nude rats with anti-CD7 ricin toxin A chain immunotoxin.

U Herrlinger1, H Schmidberger, R Buchholz, M Wehrmann, D A Vallera, M Schabet.   

Abstract

We have established a new xenogeneic animal model of leptomeningeal metastasis (LM) by intracisternal inoculation of human CEM T-cell lymphoma into nude rats, and used it to evaluate the anti-lymphoma efficacy of an anti-CD7 ricin A chain immunotoxin (DA7). In vitro incubation with 2 microg/ml DA7 for 72 h inhibited CEM cells by 90% in a trypan blue exclusion assay. To establish its anti-lymphoma activity, one and four days after cisternal inoculation of 10(6) CEM cells, eight animals each were treated cisternally with 10 microg DA7 in 50 microl PBS or sham-treated with 50 microl PBS. Histopathologically, all eight sham-treated and five of eight DA7 treated animals showed typical features of LM with multilayers of tumor cells along the whole subarachnoid space and the ventricular walls, as well as subependymal and diffuse parenchymal tumor cell infiltration. Three DA7 treated animals were free of tumor. Two of these animals were asymptomatic long-term survivors (> 90 days). The third tumor-free animal suddenly died on day 51. Histology revealed viral myocarditis. Median symptom-free survival was 51 days (range 29-90+ days) in DA7 treated and 34 days (range 29-87 days) in sham-treated animals (p = 0.12, log-rank test). Histologically, no signs of neurotoxicity or systemic toxicity was found. However, DA7 treated animals showed a tendency to a slower weight increase on days 6-28 after tumor cell inoculation. Our results indicate that this model is useful in studying leptomeningeal seeding and intracisternal treatment of lymphoma. The demonstrated anti-tumor effect of DA7 treatment deserves further evaluation especially regarding the application of DA7 in early stages of LM from T-cell lymphoma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9874180     DOI: 10.1023/a:1005815503950

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  25 in total

1.  Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Authors:  M C Alley; D A Scudiero; A Monks; M L Hursey; M J Czerwinski; D L Fine; B J Abbott; J G Mayo; R H Shoemaker; M R Boyd
Journal:  Cancer Res       Date:  1988-02-01       Impact factor: 12.701

2.  Relationship between internalization and cytotoxicity of ricin A-chain immunotoxins.

Authors:  F W Preijers; W J Tax; T De Witte; A Janssen; H vd Heijden; H Vidal; J M Wessels; P J Capel
Journal:  Br J Haematol       Date:  1988-11       Impact factor: 6.998

3.  Purification of ricin A1, A2, and B chains and characterization of their toxicity.

Authors:  R J Fulton; D C Blakey; P P Knowles; J W Uhr; P E Thorpe; E S Vitetta
Journal:  J Biol Chem       Date:  1986-04-25       Impact factor: 5.157

4.  Immunotoxins: will their clinical promise be fulfilled?

Authors:  D A Vallera
Journal:  Blood       Date:  1994-01-15       Impact factor: 22.113

5.  CNS leukemia: problem of diagnosis, treatment, and outcome.

Authors:  P G Steinherz
Journal:  J Clin Oncol       Date:  1995-02       Impact factor: 44.544

6.  Clearance of macromolecular and particulate substances from the cerebrospinal fluid system of the rat.

Authors:  J D Mann; A B Butler; R N Johnson; N H Bass
Journal:  J Neurosurg       Date:  1979-03       Impact factor: 5.115

7.  Intrathecal ACNU treatment of B16 melanoma leptomeningeal metastasis in a new athymic rat model.

Authors:  M Schabet; P Ohneseit; R Buchholz; L Santo-Höltje; H Schmidberger
Journal:  J Neurooncol       Date:  1992-10       Impact factor: 4.130

8.  Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients.

Authors:  W R Wasserstrom; J P Glass; J B Posner
Journal:  Cancer       Date:  1982-02-15       Impact factor: 6.860

9.  In vivo efficacy of intrathecal transferrin-Pseudomonas exotoxin A immunotoxin against LOX melanoma.

Authors:  W A Hall; A Myklebust; A Godal; J M Nesland; O Fodstad
Journal:  Neurosurgery       Date:  1994-04       Impact factor: 5.315

10.  Targeted therapy with immunotoxins in a nude rat model for leptomeningeal growth of human small cell lung cancer.

Authors:  A T Myklebust; A Godal; O Fodstad
Journal:  Cancer Res       Date:  1994-04-15       Impact factor: 13.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.